Inhibikase Therapeutics Dr. Milton Werner tells Proactive the biotechnology group will have six Phase 2 programs running in 2022, and will begin to report outcomes on what he believes to be its' 'transformational' Parkinson's Disease candidate. Dr. Werner says the company is gearing up for its Phase 2a clinical trial, with 7 out of 40 sites already selected, and patient dosing to occur in the next 4-5 weeks.
Inhibikase Therapeutics shares progress on its 'transformational' Parkinson's Disease candidate
